Bullish Case: Recent positive trial results for TARA-002 could drive significant price appreciation, leveraging investor sentiment, and attracting biotech sector interest. Historical trends support strong upside potential post-positive trial announcements, indicating favorable market conditions for TARA.

Bearish Case: Continued skepticism around the company's earlier trial performances and financing could lead to further declines. High implied volatility suggests that the market is primed for potential negative news, creating downward pressure on TARA’s stock price.

Potential Outcomes:

• Positive ADVANCED-2 trial results (45%) could lead to a price surge of 50%.
• Financing setbacks (35%) could result in a price drop of 20%.
• Mixed trial results (20%) might lead TARA to hover with slight declines.

Trading Oracle: Engage in a bullish strategy using TARA 12/20/2024 5.00 C as a core position, supported by the recent positive trial sentiment and elevated implied volatility. Pair with TARA 01/17/2025 5.00 P to hedge downside risk thoroughly. Expect volatility leverage for profit realization before key announcements.

December 19, 2024